Related molecule · AKG, 2-oxoglutarate, calcium alpha-ketoglutarate, Ca-AKG
A central metabolic intermediate with mouse healthspan findings and unfinished human geroscience questions.
AKG has been studied in a randomized human geroscience program but has no FDA-approved use for aging, biological-age reduction, frailty, or disease prevention.
- ABLE randomized human study protocol
Alpha-ketoglutarate has a Phase 2 biological-age trial record and a published protocol, but no FDA-approved anti-aging, frailty, or disease-prevention use.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Body Protection Compound 157
An experimental synthetic peptide popular online despite very limited reliable human evidence.
BPC-157 is not FDA approved. A Phase 2 hamstring-strain trial is registered, and FDA lists BPC-157 among bulk substances for which compounded products may present significant safety risks and for which safety information is limited.
Read evidence and limitationsPeptide · Vyleesi, PT-141
A melanocortin-receptor peptide approved for a narrowly defined sexual-desire disorder.
Vyleesi is FDA approved for acquired, generalized hypoactive sexual desire disorder in specified premenopausal women. The label explicitly excludes sexual-performance enhancement and use in men or postmenopausal women.
- FDA prescribing information: Vyleesi
Bremelanotide is approved under the Vyleesi label for a defined indication and population. That status does not make it a general libido, mood, or performance treatment.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · AM833, long-acting amylin analog
An investigational long-acting amylin analog studied alone and with semaglutide for obesity and type 2 diabetes.
Cagrilintide and CagriSema remain investigational in the United States. Completed and ongoing Phase 3 trials do not equal FDA approval.
- ClinicalTrials.gov: REDEFINE 1
Cagrilintide and CagriSema have Phase 3 records and reports, but no FDA-approved product. Combination evidence should not be treated as cagrilintide-only approval.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · CJC-1295 DAC
An unapproved growth hormone-releasing hormone analog with limited human data.
CJC-1295 is not FDA approved. FDA has identified limited clinical data and potential safety risks related to compounded products containing CJC-1295.
- FDA: bulk substances that may present significant safety risks
A Phase 2 CJC-1295 study in HIV-associated visceral obesity was terminated, and FDA has not approved a CJC-1295 product. The current public record does not show an active approval path.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsRelated molecule · creatine monohydrate, methylguanidineacetic acid
A well-studied performance supplement with credible muscle evidence and a less certain cognitive-aging frontier.
Creatine is marketed as a dietary supplement and is not an FDA-approved drug for muscle loss, cognition, aging, or disease treatment.
Read evidence and limitationsRelated molecule · D+Q, DQ senolytic combination
An experimental senolytic pairing that combines a serious cancer medicine with a flavonoid.
The D+Q combination has no FDA-approved senolytic or geroscience use. Dasatinib alone is FDA approved for specific leukemia indications under prescription labeling.
- FDA prescribing information: Sprycel
Dasatinib alone is FDA approved for leukemia indications, but the dasatinib-plus-quercetin senolytic claim remains in small pilot research rather than a defined FDA approval path.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Forzinity, SS-31, MTP-131, Bendavia
A mitochondria-targeting peptide with an accelerated FDA approval for a narrow Barth syndrome indication.
FDA granted accelerated approval to Forzinity for improving muscle strength in adults and children with Barth syndrome weighing at least 30 kilograms. A post-marketing confirmatory trial is registered, and continued approval may depend on verification of clinical benefit.
- Forzinity: Barth syndrome — accelerated approval
Subcutaneous injection; Patients with Barth syndrome weighing at least 30 kg. Confirmatory evidence of patient benefit is required. This is not approval for primary mitochondrial myopathy generally.
Source checked: 2026-09-18
- MMPOWER-3
Genetically confirmed primary mitochondrial myopathy; 24 weeks. Neither primary endpoint was met. Primary mitochondrial myopathy is not interchangeable with the approved Barth syndrome population.
Source checked: 2026-09-18
Read evidence and limitationsPeptide · Byetta, Bydureon, exendin-4
An FDA-approved diabetes peptide whose promising Phase 2 Parkinson signal failed in a larger Phase 3 trial.
FDA-approved exenatide products have specific type 2 diabetes indications. No exenatide product is FDA approved for Parkinson disease, cognition, or neuroprotection.
- FDA prescribing information: Byetta
Exenatide is approved under product-specific diabetes labeling. Parkinson's and other investigational uses remain separate from that approval.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsRelated molecule · senolytic flavonoid, dietary fisetin
A plant flavonoid with striking mouse senolytic findings but no proven human longevity or frailty benefit.
Fisetin is being studied in human trials but has no FDA-approved drug use for senescence, frailty, cardiovascular aging, cancer recovery, or longevity. Supplement products are not FDA approved for effectiveness.
- ClinicalTrials.gov: AFFIRM-LITE
Fisetin has a small Phase 2 frailty trial record and early human mechanistic research, but no FDA-approved senolytic, frailty, or longevity indication.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · copper tripeptide-1, copper peptide GHK-Cu
A copper-binding tripeptide used in cosmetic research, with mostly laboratory and animal wound-healing evidence.
No GHK-Cu drug product is FDA approved for wound healing, hair growth, anti-aging, or systemic use. FDA identifies potential immune and impurity risks for compounded injectable GHK-Cu and limited human safety data.
Read evidence and limitationsPeptide · growth hormone-releasing peptide-2, pralmorelin
An unapproved ghrelin-receptor agonist that raises growth hormone and appetite without proven muscle-building outcomes.
GHRP-2 is not FDA approved. FDA places GHRP-2 for injectable and nasal routes in a compounding category associated with potential significant safety risks.
Read evidence and limitationsPeptide · HN, MT-RNR2 peptide, S14G-humanin (experimental analog)
A mitochondrial-derived peptide studied for cell survival, neuroprotection, metabolism, and aging mostly in preclinical work.
No humanin or humanin-analog product is FDA approved. Human therapeutic development has not produced a mature clinical program establishing benefit for cognition, neurodegeneration, metabolism, or aging.
- Humanin and cognitive aging study
Humanin research is dominated by cell, animal, genetic, and biomarker studies. The page references do not show a mature human treatment program or FDA approval.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · ipamorelin acetate
An unapproved growth hormone secretagogue with limited clinical evidence and FDA-identified concerns.
Ipamorelin is not FDA approved. FDA has described potential immunogenicity and impurity concerns and insufficient safety information for certain routes.
Read evidence and limitationsRelated molecule · BHB, beta-hydroxybutyrate, exogenous ketones, ketone monoester
Compounds that raise circulating ketones reliably but have not established cognitive or healthy-aging benefit.
Exogenous ketone formulations are being studied in human trials but are not FDA-approved drugs for cognitive decline, frailty, metabolic syndrome, or longevity.
- ClinicalTrials.gov: ketone ester brain-metabolism study
Ketone ester and beta-hydroxybutyrate formulations are in human research, including a brain-metabolism study without a conventional phase label, but the cited record does not show an FDA-approved cognitive or anti-aging drug path.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · kisspeptin-54, kisspeptin-10, metastin
A reproductive signaling peptide studied in fertility, hormone release, and brain responses.
Kisspeptin has no FDA-approved drug product. Human research includes completed Phase 2 IVF studies, while FDA has described limited safety information and potential peptide-quality concerns for compounded kisspeptin-10.
- ClinicalTrials.gov: kisspeptin in IVF
Kisspeptin has human Phase 2 research in IVF-related triggering, but it has no FDA-approved product or broad reproductive, mood, or wellness indication.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Linzess, guanylate cyclase-C agonist
A minimally absorbed peptide medicine approved for several constipation disorders in defined adult and pediatric populations.
Current FDA labeling covers IBS with constipation, chronic idiopathic constipation, and pediatric functional constipation in the specific age groups listed for each indication.
- FDA prescribing information: Linzess
Linaclotide is approved under the Linzess label for specific adult and pediatric constipation-related indications. The approval is label-specific.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Victoza, Saxenda
An established GLP-1 medicine approved for specific diabetes and weight-management uses.
FDA-approved liraglutide products have indications for type 2 diabetes or chronic weight management in defined populations. Check current labeling for age and eligibility details.
- Victoza: Cardiovascular outcomes — approved
Subcutaneous injection; Adults with type 2 diabetes and established cardiovascular disease. Does not transfer to people without diabetes or establish general longevity benefit.
Source checked: 2026-09-18
- LEADER
Type 2 diabetes and high cardiovascular risk; Median follow-up 3.8 years. 608/4668 (13.0%) versus 694/4672 (14.9%) had a primary event. Population differs from SELECT; these two placebo comparisons cannot rank liraglutide against semaglutide.
Source checked: 2026-09-18
Read evidence and limitationsPeptide · Adlyxin, Lyxumia, lixisenatide acetate
A discontinued U.S. GLP-1 product with established diabetes evidence and an encouraging but unconfirmed Parkinson trial.
FDA records list the U.S. Adlyxin presentations as discontinued. The prior approval covered glycemic control in adults with type 2 diabetes, not Parkinson disease.
- FDA Purple Book: Adlyxin product status
Lixisenatide had an FDA-approved diabetes product, but the cited FDA product record and label context support treating the U.S. product as discontinued rather than currently marketed.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsRelated molecule · Glucophage, metformin hydrochloride
A foundational diabetes medicine being studied in geroscience, without an approved anti-aging use.
Metformin is FDA approved for glycemic control in type 2 diabetes. Aging, lifespan extension, and general healthspan enhancement are not FDA-approved indications.
Read evidence and limitationsPeptide · MOTS-c peptide, mitochondrial ORF of 12S rRNA type-c
A mitochondrial-derived peptide with intriguing metabolic and exercise biology but no proven human therapy.
No MOTS-c drug product is FDA approved. FDA's current compounding safety summary states that it has not identified human exposure data for drug products containing MOTS-c.
Read evidence and limitationsRelated molecule · nicotinamide adenine dinucleotide, NAD
A central cellular coenzyme with legitimate biology but little clinical-outcomes evidence for wellness infusions.
The linked FDA communication is a compounding safety warning, not an approval decision. The scoped record below documents this limited search; it should not be read as an exhaustive inventory of drug applications or jurisdictions.
- NAD+: Wellness and aging — search incomplete
Compounded products; formulation varies; Wellness populations. The linked FDA warning documents compounding risks, not an approved indication. This page has not completed an exhaustive Drugs@FDA ingredient/alias search.
Source checked: 2026-09-18
- NAD+ metabolome pilot
Human infusion cohort; full participant details not extracted; Six-hour exposure with short-term sampling. The report describes metabolite handling during and after exposure. Does not measure longevity, addiction recovery, cognition or durable functional benefit. Sample size and full risk assessment are not extracted.
Source checked: 2026-09-18
Read evidence and limitationsRelated molecule · NMN, beta-NMN
An NAD+ precursor with small human trials and unresolved real-world clinical value.
NMN has no FDA-approved drug indication for aging or any consumer wellness goal. Product-specific U.S. marketing status is a separate legal question from whether a health claim is clinically proven.
- MIB-626 NMN study
Adults aged ≥45 with overweight or obesity; 28 days. Circulating NAD increased; strength, fatigability, aerobic capacity and stair-climbing changes did not differ significantly. Multiple short-term outcomes; no inference about lifespan. This formulation cannot represent every NMN product.
Source checked: 2026-09-18
Read evidence and limitationsRelated molecule · NR, niagen
An NAD+ precursor that reliably changes biomarkers but has not shown a consistent anti-aging or cognitive benefit.
No nicotinamide-riboside drug is FDA approved to prevent or treat aging, cognitive decline, mitochondrial dysfunction, or fatigue. Dietary-supplement marketing does not equal FDA approval.
- NR mild cognitive impairment pilot
Older adults with mild cognitive impairment; 10 weeks. Blood NAD+ increased; cognition did not change. Too small and short to establish prevention of dementia or rare harms. Cerebral blood-flow findings did not survive correction for multiple comparisons.
Source checked: 2026-09-18
Read evidence and limitationsPeptide · Pitocin, synthetic oxytocin
A natural peptide hormone with approved obstetric products and unproven intranasal cognitive or social uses.
FDA-approved oxytocin products have specific obstetric indications. No intranasal oxytocin product is FDA approved for autism, cognition, social functioning, mood, or consumer wellness goals.
- FDA prescribing information: Pitocin
Oxytocin is FDA approved under product-specific labeling for obstetric use. That approval does not validate autism, bonding, cognition, or wellness claims.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · ALT-801
An investigational glucagon/GLP-1 dual agonist in mid-stage research for MASH, liver fat, and obesity.
Pemvidutide remains investigational in the United States. Its MASH and obesity programs have not produced an FDA-approved product.
- Randomized pemvidutide MASLD study
Pemvidutide has Phase 2 evidence and a completed Phase 2b MASH program, but confirmatory development and regulatory review remain unresolved.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Trulance, uroguanylin analog
An FDA-approved gut-signaling peptide for chronic idiopathic constipation and IBS with constipation in adults.
Trulance is FDA approved for adults with chronic idiopathic constipation and adults with irritable bowel syndrome with constipation.
Read evidence and limitationsPeptide · Symlin, pramlintide acetate
An FDA-approved amylin analog for selected insulin-treated diabetes patients, with unapproved weight-management research.
Symlin is FDA approved as an adjunct for selected adults with type 1 or type 2 diabetes who use mealtime insulin and have not achieved desired glucose control despite appropriate insulin management.
- FDA prescribing information: Symlin
Pramlintide is approved under the Symlin label for specified insulin-treated diabetes populations. Its investigational weight history does not create a weight-loss approval.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · LY3437943
An investigational triple-receptor agonist in Phase 3 clinical trials.
Retatrutide is not FDA approved. Some Phase 3 studies have reported company-provided top-line results, while other Phase 3, head-to-head, and outcomes studies remain ongoing or active in registries.
- Retatrutide Phase 2
Adults with obesity or overweight plus a weight-related condition; 48 weeks; primary endpoint at 24 weeks. Greater weight reductions than placebo were reported. A Phase 2 result is neither approval nor a direct comparison with semaglutide or tirzepatide.
Source checked: 2026-09-18
- TRIUMPH-1
Adults with obesity or overweight; defined substudies; Primary weight endpoint: 80 weeks. Registry marks the study completed; no results are posted in this registry snapshot. No posted registry results does not mean no results exist elsewhere. Publication search is not complete.
Source checked: 2026-09-18
- TRIUMPH-5
Adults with obesity; Primary weight endpoint: 80 weeks. Active, not recruiting; no registry results posted at the source check. A registered head-to-head design is not a completed head-to-head result. Enrollment is estimated.
Source checked: 2026-09-18
Read evidence and limitationsPeptide · PTG-300, Mimrylo
A hepcidin-mimetic peptide approved as Mimrylo for erythrocytosis in adults with polycythemia vera.
FDA approved Mimrylo for erythrocytosis in adults with polycythemia vera. Earlier application-acceptance and priority-review records are historical milestones, superseded by the approval decision.
Read evidence and limitationsPeptide · Selank acetate, TP-7
An unapproved synthetic heptapeptide studied for anxiety, with a thin and uncertain human evidence base.
Selank has no FDA-approved drug product or use. FDA's current compounding safety summary states that important human safety information is lacking and describes peptide-quality and immune-reaction concerns.
- FDA: safety risks for selected compounded bulk substances
Selank is not FDA approved. Limited human and mechanistic research does not establish an active FDA drug-development program or an approved anxiety treatment.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Ozempic, Wegovy, Rybelsus
A GLP-1 medicine with FDA-approved products for type 2 diabetes and chronic weight management.
Semaglutide approvals are product-specific. Wegovy injection and tablets have distinct population scopes. Wegovy injection also has an accelerated-approval indication for adults with noncirrhotic MASH and F2–F3 fibrosis; that indication is not assigned to tablets in the reviewed label. Other products have their own diabetes, kidney or cardiovascular label scope.
- Wegovy: Weight management — approved
Subcutaneous injection; Adults with obesity or overweight plus a weight-related condition; ages 12+ with obesity. Adjunct to reduced-calorie diet and increased physical activity. This is label scope, not a recommendation.
Source checked: 2026-09-18
- Wegovy: Weight management — approved
Oral tablet; Adults with obesity or overweight plus a weight-related condition. Do not transfer pediatric injection scope to tablets.
Source checked: 2026-09-18
- Wegovy: MASH — accelerated approval
Subcutaneous injection; Adults with noncirrhotic MASH and fibrosis consistent with F2–F3. Based on MASH and fibrosis improvement; continued approval may depend on confirmatory clinical benefit.
Source checked: 2026-09-18
- Wegovy: MASH — not in label
Oral tablet; MASH population. The reviewed label assigns this indication to injection, not tablets. Absence from this label is not a global regulatory search.
Source checked: 2026-09-18
- Wegovy: Cardiovascular outcomes — approved
Subcutaneous injection; Adults with established cardiovascular disease and overweight or obesity. Risk reduction for cardiovascular death, nonfatal myocardial infarction or nonfatal stroke.
Source checked: 2026-09-18
- SELECT
Age 45+, established cardiovascular disease, BMI ≥27, no diabetes; Mean follow-up 39.8 months. 569/8803 (6.5%) versus 701/8801 (8.0%) had a primary event. A secondary-prevention population; not a trial in healthy adults or a head-to-head comparison.
Source checked: 2026-09-18
Read evidence and limitationsPeptide · Semax heptapeptide, ACTH(4-7)-Pro-Gly-Pro
An unapproved neuroactive heptapeptide with old, small human studies and substantial evidence gaps.
Semax has no FDA-approved drug product or use. FDA's current compounding safety page identifies potential immune and impurity risks and limited safety information for proposed routes.
Read evidence and limitationsPeptide · Geref, sermorelin acetate
A growth hormone-releasing hormone analog whose former FDA-approved product was discontinued.
The FDA-approved Geref product is discontinued from marketing. Current compounded sermorelin products are not FDA-approved drug products, and discontinuation history should be checked in Drugs@FDA.
- Federal Register: Geref discontinuation determination
Geref, a sermorelin acetate product, was discontinued. A discontinued product is not the same as a currently marketed FDA-approved option for wellness or anti-aging use.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Imcivree, RM-493
An MC4-receptor peptide medicine approved for obesity caused by specific rare genetic conditions.
The Imcivree label covers acquired hypothalamic obesity from age 4, and specified POMC, PCSK1 or LEPR deficiency or Bardet-Biedl syndrome from age 2. These are distinct populations; general obesity remains outside the indication.
- Imcivree: Acquired hypothalamic obesity — approved
Subcutaneous injection; Adults and children aged at least 4 with acquired hypothalamic obesity. Not an indication for general obesity. Acquired hypothalamic obesity has specific warnings.
Source checked: 2026-09-18
- Imcivree: Specified genetic obesity — approved
Subcutaneous injection; Age 2+ with BBS or specified genetically confirmed POMC, PCSK1 or LEPR deficiency. Genetic eligibility and limitations are defined in the label; not all variants qualify.
Source checked: 2026-09-18
Read evidence and limitationsRelated molecule · rapamycin, Rapamune
An FDA-approved immunosuppressant with serious risks and unproven longevity use in healthy people.
FDA-approved sirolimus products have specific indications, including prevention of organ rejection in selected kidney-transplant patients and treatment of lymphangioleiomyomatosis. Aging and longevity are not approved indications.
- FDA prescribing information: Rapamune
Sirolimus is FDA approved under Rapamune labeling for defined medical uses. Healthy-aging or longevity use remains investigational and should not be folded into the approval.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsRelated molecule · dietary spermidine, polyamine
A food-derived polyamine linked to autophagy biology, with a negative phase 2 cognitive primary outcome.
Spermidine is not an FDA-approved drug for memory, cognitive decline, dementia prevention, autophagy enhancement, or aging. Dietary supplements are not preapproved by FDA for effectiveness.
- SmartAge randomized clinical trial
Spermidine has dietary and supplement research, including a negative primary memory outcome in a Phase 2b cognitive trial, but no FDA-approved drug use.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · BI 456906
An investigational glucagon/GLP-1 dual agonist in Phase 3 research for obesity and metabolic liver disease.
Survodutide remains investigational in the United States and is being evaluated in Phase 3 obesity and metabolic liver-disease programs.
- Randomized Phase 2 MASH trial
Survodutide has Phase 3 trial evidence and registry records, but it remains investigational until an FDA review supports approval for a defined use.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsRelated molecule · 2-aminoethanesulfonic acid
A common nutrient-related molecule whose animal longevity story is challenged by human aging data.
No taurine drug is FDA approved to slow aging, extend lifespan, prevent frailty, or improve general performance. Supplement marketing does not equal FDA-reviewed effectiveness.
- Taurine deficiency as a driver of aging
Taurine is a normal nutrient-related molecule with animal and observational aging research, but no FDA-approved drug use for lifespan, frailty, or general performance.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Gattex, Revestive, GLP-2 analog
An FDA-approved GLP-2 analog that improves intestinal absorption in short bowel syndrome dependent on parenteral support.
Gattex is FDA approved for adults and pediatric patients 1 year of age and older with short bowel syndrome who are dependent on parenteral support.
- FDA prescribing information: Gattex
Teduglutide is approved under the Gattex label for short bowel syndrome with parenteral-support dependence in specified age groups.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Egrifta SV
A growth hormone-releasing factor analog approved for a narrow HIV-related indication.
Egrifta SV is FDA approved to reduce excess abdominal fat in HIV-infected adult patients with lipodystrophy. It is not indicated for general weight-loss management.
- FDA prescribing information: Egrifta SV
Tesamorelin's approval is tied to the Egrifta label and HIV-associated lipodystrophy. It should not be generalized to ordinary weight loss or anti-aging claims.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Tα1, thymalfasin, Zadaxin
An immune-modulating peptide used in some countries but not FDA approved for any U.S. indication.
Thymosin alpha-1 has no FDA-approved product or indication. FDA has specifically stated that it is not approved to treat or prevent COVID-19 or any other condition and identifies compounded-product evidence and quality concerns.
- FDA: safety risks for selected compounded bulk substances
Thymosin alpha-1 has human studies and non-U.S. product history, but FDA states it has no approved U.S. indication and identifies compounded-product concerns.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Tβ4, TB4, full-length thymosin beta-4, TB-500 (fragment marketed online)
A naturally occurring peptide studied in tissue repair; marketed fragments are not FDA approved.
No thymosin beta-4 or TB-500 product is FDA approved for consumer recovery or performance uses. FDA has specifically described evidence gaps and potential risks for the thymosin beta-4 fragment used in compounding.
Read evidence and limitationsPeptide · Mounjaro, Zepbound
A dual GIP/GLP-1 receptor agonist approved for specific metabolic and sleep-apnea uses.
Tirzepatide products are FDA approved for specific uses, including type 2 diabetes, chronic weight management, and—under the Zepbound label—moderate-to-severe obstructive sleep apnea in adults with obesity.
- Zepbound: Weight management — approved
Subcutaneous injection; Adults with obesity or overweight plus a weight-related condition. Adjunct to reduced-calorie diet and increased physical activity.
Source checked: 2026-09-18
- Zepbound: Obstructive sleep apnea — approved
Subcutaneous injection; Adults with obesity and moderate-to-severe obstructive sleep apnea. Does not cover every cause or severity of sleep apnea.
Source checked: 2026-09-18
- SURMOUNT-1
Adults with obesity or overweight plus a complication; diabetes excluded; 72 weeks. Active groups had greater mean weight reduction than placebo. Weight change alone does not quantify cardiovascular-event or survival benefit; different active regimens are not pooled here.
Source checked: 2026-09-18
- TRIUMPH-5
Adults with obesity; Primary weight endpoint: 80 weeks. Active, not recruiting; no registry results posted at the source check. A registered head-to-head design is not a completed head-to-head result. Enrollment is estimated.
Source checked: 2026-09-18
Read evidence and limitationsPeptide · Daybue, NNZ-2566
An FDA-approved synthetic peptide analog for Rett syndrome with modest trial benefits and frequent gastrointestinal adverse effects.
FDA-approved Daybue labeling covers treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.
- FDA prescribing information: Daybue
Trofinetide is approved under the Daybue label for Rett syndrome in specified ages. The approval should not be generalized to other neurodevelopmental or cognitive claims.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsRelated molecule · UA, pomegranate-derived postbiotic
A mitophagy-related metabolite with human biomarker and muscle-endurance signals but no approved disease use.
Urolithin A is not an FDA-approved drug for any aging, muscle, mitochondrial, or immune indication. Supplement availability is not evidence of FDA-reviewed effectiveness.
- Randomized urolithin A trial in older adults
Urolithin A has human supplement-style trials and biomarker outcomes, but no FDA-approved drug indication for mitochondrial health, muscle function, or aging.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Voxzogo
A C-type natriuretic peptide analog approved to increase growth in children with achondroplasia.
Voxzogo is FDA approved under accelerated approval to increase linear growth in pediatric patients with achondroplasia and open epiphyses. The FDA later removed its minimum-age restriction.
- FDA prescribing information: Voxzogo
Vosoritide is FDA approved under the Voxzogo label for children with achondroplasia and open growth plates, with accelerated-approval context and follow-up evidence remaining important.
Check date not recorded; consult the linked source for current details.
Read evidence and limitationsPeptide · Prialt, SNX-111
A cone-snail-inspired peptide medicine approved for severe chronic pain under specialist care.
Prialt is FDA approved for severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment.
- FDA prescribing information: Prialt
Ziconotide is approved under the Prialt label for intrathecal treatment of severe chronic pain in a narrow clinical context, not as a general pain remedy.
Check date not recorded; consult the linked source for current details.
Read evidence and limitations